Want to see SNTI full AI Analyst Report?
SNTI Stock Chart & Stats
$0.39
>-$0.01(-0.97%)
At close: 4:00 PM EDT
$0.39
>-$0.01(-0.97%)
Day’s Range― - ―
52-Week Range$0.21 - $2.88
Previous CloseN/A
Volume63.62K
Average Volume (3M)1.59M
Market Cap
$7.06M
Enterprise Value$40.95M
Total Cash (Recent Filing)$6.46M
Total Debt (Recent Filing)$20.23M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding31,145,390
10 Day Avg. Volume2,433,551
30 Day Avg. Volume1,591,856
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)41.84
Price to Sales (P/S)10628.51
P/FCF Ratio-5.36
Enterprise Value/Market Cap5.80
Enterprise Value/Revenue744.48
Enterprise Value/Gross Profit-27.21
Enterprise Value/Ebitda-0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$58.00K
Bulls Say, Bears Say
Bulls Say
Gene-circuit PlatformSenti’s gene-circuit platform targets a meaningful therapeutic challenge by programming cells to sense disease signals and control activity. If clinical work validates this approach, the technology could support differentiated oncology applications and broader platform value over multiple development cycles.
Merger ExecutionShareholder approval removes important governance hurdles for the planned merger and restructuring. Completing these actions could reshape the capital structure, support continued strategic execution, and provide a clearer framework for financing and development of the company’s therapeutic programs.
Financing SupportThe equity commitment provides a defined source of capital linked to the merger process, helping support operations and transaction execution in the near term. Although modest relative to the company’s losses, financing access can extend development capacity while strategic restructuring proceeds.
Bears Say
Minimal Revenue And Deep LossesCommercial traction remains extremely limited while operating costs substantially exceed revenue. Persistent large losses reduce the company’s ability to self-fund research and development, making future progress dependent on financing, partnerships, or successful clinical and product milestones.
Persistent Cash BurnSenti continues to consume significant cash to fund operations, even though its burn rate improved from 2025. Ongoing negative operating and free cash flow can shorten the funding runway and increase dependence on additional capital before products generate meaningful commercial cash inflows.
Balance-sheet And Listing PressureNegative equity weakens financial flexibility and creates a structural financing constraint for a clinical-stage company. Nasdaq’s notices add potential delisting and reverse-split pressure, which could complicate capital raising and increase uncertainty around the company’s future market access.
Senti Biosciences News
SNTI FAQ
What was Senti Biosciences’s price range in the past 12 months?
Senti Biosciences lowest stock price was $0.21 and its highest was $2.88 in the past 12 months.
What is Senti Biosciences’s market cap?
Senti Biosciences’s market cap is $7.06M.
When is Senti Biosciences’s upcoming earnings report date?
Senti Biosciences’s upcoming earnings report date is Nov 12, 2026 which is in 23 days.
How were Senti Biosciences’s earnings last quarter?
Senti Biosciences released its earnings results on May 14, 2026. The company reported -$0.14 earnings per share for the quarter.
Is Senti Biosciences overvalued?
According to Wall Street analysts Senti Biosciences’s price is currently Overvalued.
Does Senti Biosciences pay dividends?
Senti Biosciences does not currently pay dividends.
What is Senti Biosciences’s EPS estimate?
Senti Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senti Biosciences have?
Senti Biosciences has 31,145,390 shares outstanding.
What happened to Senti Biosciences’s price movement after its last earnings report?
Senti Biosciences reported an EPS of -$0.14 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Senti Biosciences?
Currently, no hedge funds are holding shares in SNTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senti Biosciences
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
Technical Analysis
Ownership Overview
2.63% Insiders
0.46% Mutual Funds
0.11% Other Institutional Investors
95.06% Public Companies and
Individual Investors